REGENXBIO Inc. today reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY DUCHENNE® trial of RGX-202, a differentiated investigational gene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback